IOLCP Gets China NMPA Approval for Clopidogrel API

Date: 14th July 2026

Regulatory Approval Update

• The Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted approval for the Company's API product "Clopidogrel Bisulfate" on 14th July 2026.
• This approval represents an additional regulatory certification beyond the existing valid Certificate of Suitability (CEP) already held by the Company for the same product.
• The approval strengthens the Company's regulatory portfolio and expands its market access to the Chinese pharmaceutical market.

Disclosure Context

• The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
• The announcement was signed by Abhay Raj Singh, Sr. Vice President & Company Secretary, and digitally timestamped on 14th July 2026 at 16:30:37 IST.